UK Paediatric Hyperthyroidism Management Survey of Clinicians, 2018

98% of surveyed UK paediatric endocrinologists favour carbimazole for treating hyperthyroidism. The dataset contains responses to a 27-question online survey distributed in August 2018 to members of the British Society for Paediatric Endocrinology and Diabetes, documenting practices in anti-thyroid drug use, treatment duration, and patient monitoring. It was authored by Neil Lawrence and published via Papers with Code under an Open Access license.

Use Cases

• Analyze clinician preferences for anti-thyroid drug regimens based on the reported 65% preference for 'dose titration' over 'block and replace'.
• Study patient education practices based on the reported 63% 'rarely/never' providing written information on agranulocytosis risk.
• Compare diagnostic and remission monitoring practices based on the reported 85% use of TRAbs for diagnosis and 33% for remission evidence.
• Model treatment duration patterns based on the reported 81% treating for a minimum of 2 years before considering stopping medication.

Strengths

• Survey includes responses from a targeted professional society, the British Society for Paediatric Endocrinology and Diabetes.
• Results contain specific, quantified findings such as 98% carbimazole preference and 81% minimum 2-year treatment duration.
• Survey design is documented with 27 questions covering drug preference, treatment duration, and monitoring criteria.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

Papers with Code, authored by Neil Lawrence.

Collection Method

27-question online survey distributed via an electronic newsletter in August 2018.

Time Range

Survey conducted in August 2018.

Geography

United Kingdom, specifically clinicians belonging to the British Society for Paediatric Endocrinology and Diabetes.